Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Aprea Therapeutics

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio
From Aprea Therapeutics
Via GlobeNewswire
Tickers APRE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.